Figure 4.
Molecular targeted therapies in HCC. Tyrosine kinase and mTOR inhibitors in preclinical studies or clinical trials for HCC. Some monoclonal antibodies directed against tyrosine kinase receptors are also indicated (Modified from [47]).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.